Reuters: Health
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
Results of GSK and AstraZeneca trials may widen ovarian cancer drug use
Results of GSK and AstraZeneca trials may widen ovarian cancer drug use
Reuters: Health
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
Reuters: Health
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment